- cafead   Dec 15, 2021 at 10:52: AM
via Cancer treatment specialist BeiGene Ltd plunged 16.4% on its Shanghai debut on Wednesday after raising $3.5 billion, hit by concerns over its valuation amid potential U.S. sanctions on Chinese biotech companies.
article source
article source